Finally, we identified strong evidence for a detrimental effect of higher FHL3 expression on both overall and male-specific CRC risk across several subtypes of CD4+ T cells during rest and at three post-activation timepoints (Figure 5). This evidence concerns the gene FHL3 and colorectal carcinoma.